Formulary Search Results for: USTEKINUMAB
If the searched medicine is not listed in the NHSGGC Formulary, please check if the relevant therapeutic chapter is now available on the West of Scotland Formulary — visit formulary.nhs.scot/west.
10.1.3 Drugs that suppress the rheumatic disease process - View Category
Total Formulary
USTEKINUMAB
Restrictions:
The use as monotherapy or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate, is restricted to specialist use in patients with active psoriatic arthritis who have failed on, or are unsuitable for, treatment with an anti-TNF drug.
Prescribing Notes:
Ustekinumab should be prescribed by brand name. Wezenla® is the preferred biosimilar.
For use in psoriasis, see section 13.5.3.